Tempus AI stock rises 3.5% after unveiling HRD-RNA algorithm for cancer detection

What's Going On With Tempus AI Stock Today? - Tempus AI (NASDAQ:TEM)

Tempus AI (NASDAQ:TEM) rose on Wednesday after the company unveiled its new HRD-RNA algorithm, an AI-driven tool designed to improve detection of homologous recombination deficiency (HRD) in tumors. The next-generation model analyzes gene expression to help identify patients who may benefit from platinum-based chemotherapy or PARP inhibitors, offering what the company says is a more dynamic assessment of tumor biology than traditional genomic methods. In a real-world validation study, HRD-RNA-positive metastatic pancreatic cancer patients treated with first-line platinum-based regimens saw a significant reduction in mortality risk compared with those receiving non-platinum therapies. Tempus plans to make the test clinically available later this year. Chief Development Officer Halla Nimeiri said the algorithm provides physicians with a more functional view of HRD status by examining the transcriptome rather than the genome alone. Technical Analysis Currently, the stock is trading 8.3% below its 20-day simple moving average (SMA) and 25.8% below its 100-day SMA, indicating a bearish trend in the short to medium term. Shares have decreased 35.86% over the past 12 months and are positioned closer to their 52-week lows than highs. The RSI is at 35.53, which is considered neutral territory, while the MACD shows a value of -3.9401, below its signal line at -3.3917, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum, reflecting uncertainty in the stock's near-term performance. Key Resistance: $61.50 Key Support: $50.00 The launch of the HRD-RNA algorithm highlights Tempus's commitment to leveraging AI in healthcare to enhance treatment options for patients. This innovative approach positions the company as a leader in precision medicine, potentially improving patient outcomes and expanding its market reach. Earnings & Analyst Outlook The countdown is on: Tempus AI is set to report earnings on February 24, 2026. EPS Estimate: Loss of 13 cents (Up from Loss of 18 cents YoY) Revenue Estimate: $364.25 million (Up from $200.68 million YoY) Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $76.60. Recent analyst moves include: Baird: Initiated with Outperform (Target $59.00) (Feb. 17) Canaccord Genuity: Buy (Lowers Target to $80.00) (Dec. 22, 2025) JP Morgan: Neutral (Lowers Target to $80.00) (Dec. 15, 2025) Benzinga Edge Rankings Below is the Benzinga Edge scorecard for Tempus AI, highlighting its strengths and weaknesses compared to the broader market: Momentum: Weak (Score: 5.75) -- Stock is underperforming the broader market. The Verdict: Tempus AI's Benzinga Edge signal reveals a classic 'High-Flyer' setup. While the weak momentum score indicates underperformance, innovative developments in precision medicine could catalyze future growth. Top ETF Exposure ARK Innovation ETF (NYSE:ARKK): 5.07% Weight ARK Genomic Revolution ETF (BATS:ARKG): 8.63% Weight Significance: Because TEM carries significant weight in these funds, any significant inflows or outflows will likely trigger automatic buying or selling of the stock. TEM Price Action: Tempus AI shares were up 3.41% at $54.35 during premarket trading on Wednesday, according to Benzinga Pro data. Image: Shutterstock Market News and Data brought to you by Benzinga APIs To add Benzinga News as your preferred source on Google, click here.

Tempus AI stock rises after launching new cancer detection algorithm By Investing.com

Investing.com -- Tempus AI, Inc. (NASDAQ:TEM) stock rose 3.5% Wednesday after the precision medicine technology company announced the launch of its new HRD-RNA algorithm for cancer detection. The new AI-driven model represents an advancement in identifying Homologous Recombination Deficiency (HRD), offering a more dynamic assessment of tumor biology compared to traditional DNA-based tests. The 1,660-gene logistic regression model is designed to identify patients likely to respond to platinum-based chemotherapy or PARP inhibitors. Unlike conventional DNA tests that analyze static "genomic scars," Tempus' RNA-based approach provides real-time assessment of a tumor's functional status by analyzing gene expression rather than structural DNA damage. This methodology allows the model to detect HRD in patients and cancer types where genomic scarring is difficult to identify. According to the company, a real-world validation study showed that HRD-RNA positive metastatic pancreatic patients treated with first-line platinum-based regimens demonstrated a significant reduction in mortality risk compared to those receiving non-platinum first-line therapies. The complete supporting data will be published later this year. "Our HRD-RNA algorithm gives physicians a critical tool to better inform treatment decisions," said Halla Nimeiri, MD, Chief Development Officer at Tempus. "By looking at the transcriptome, we can identify a functional HRD status that is more dynamic than what can be seen in the genome alone." The algorithm is currently available for research use only, with clinical availability expected later this year. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.